<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924413</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH L-TIL Melanoma</org_study_id>
    <nct_id>NCT04924413</nct_id>
  </id_info>
  <brief_title>L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma</brief_title>
  <official_title>L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quanli Gao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor&#xD;
      infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in&#xD;
      patients with advanced malignant melanoma. This study plan to include stage III or IV&#xD;
      unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4&#xD;
      cycles with each infusion (3 -10) x10*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W.&#xD;
      It is expected that 30 patients will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>L-TIL and Tislelizumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (ORR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The objective response rate (ORR) at 8 weeks from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (ORR)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The objective response rate (ORR) at 16 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>The duration of response (DOR) at 1-year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>The duration of response (DOR) at 2-year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>2 years</time_frame>
    <description>The adverse events followed by treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>The PFS rate at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The PFS rate at 2-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>The OS rate at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>The OS rate at 2-year.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>L-TIL and Tislelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-TIL（3-10）x10*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion</description>
    <arm_group_label>L-TIL and Tislelizumab</arm_group_label>
    <other_name>L-TIL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Pathological confirmed melanoma 2. Advanced stage confirmed by radiological examination&#xD;
        3. Untreated 4. ECOG PS 0-1 6. Good organ function 7. No other severe diseases such as&#xD;
        autoimmune disease, organ transplant, chronic infection.&#xD;
&#xD;
        8. Other tumor disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic brain metastases&#xD;
&#xD;
          2. Active infection&#xD;
&#xD;
          3. Active HBV or HCV infection&#xD;
&#xD;
          4. HIV infection&#xD;
&#xD;
          5. Autoimmune disease&#xD;
&#xD;
          6. Sensitive to drug or ingredients&#xD;
&#xD;
          7. Severe mental disorders&#xD;
&#xD;
          8. Sever disfunction of heart, liver and kidney&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quanli Gao, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quanli Gao, Ph.D</last_name>
    <phone>0371-65587483</phone>
    <email>zlyygql0855@zzu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaomin Fu, Ph.D</last_name>
    <phone>0371-65587187</phone>
    <email>52400729@qq.com</email>
  </overall_contact_backup>
  <link>
    <url>http://cancerres.aacrjournals.org/content/81/8/2184.long</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Li T, Zhao L, Yang Y, Wang Y, Zhang Y, Guo J, Chen G, Qin P, Xu B, Ma B, Zhang F, Shang Y, Li Q, Zhang K, Yuan D, Feng C, Ma Y, Liu Z, Tian Z, Li H, Wang S, Gao Q. T Cells Expanded from PD-1(+) Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes. Cancer Res. 2021 Apr 15;81(8):2184-2194. doi: 10.1158/0008-5472.CAN-20-2300. Epub 2021 Jan 6.</citation>
    <PMID>33408117</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Quanli Gao</investigator_full_name>
    <investigator_title>Head of Immunotherapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

